AbbVie said full-year 2024 net revenues were $56.334 billion, up 3.7% on a reported basis and 4.6% on an operational basis. Full-year GAAP diluted EPS was $2.39, down 12.1%, and adjusted diluted EPS was $10.12, down 8.9%.

1. 01

   AbbVie said full-year 2024 net revenues were $56.334 billion, up 3.7% on a reported basis and 4.6% on an operational basis. Full-year GAAP diluted EPS was $2.39, down 12.1%, and adjusted diluted EPS was $10.12, down 8.9%.

2. 02

   AbbVie said its GAAP diluted loss per share for Q4 2024 was $0.02, including the partial intangible asset impairment charge related to emraclidine. The company recorded a non-cash after-tax impairment charge of $3.5 billion. It said adjusted diluted EPS was $2.16.

3. 03

   The company said Skyrizi net revenues for Q4 2024 were $3.778 billion, an increase of 57.7% on a reported basis. Rinvoq revenues were $1.834 billion, up 46.2%. It said Humira revenues fell 49.1% to $1.682 billion.

4. 04

   AbbVie gave adjusted diluted EPS guidance of $12.12 to $12.32 for 2025, excluding any impact from acquired IPR&D and milestones. The company said it raised its 2027 combined Skyrizi and Rinvoq sales outlook to more than $31 billion, up from its prior outlook of more than $27 billion.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.